ESR1 and breast carcinoma: Although studies using bortezomib as a single agent to treat breast cancer were disappointing[37], new clinical studies are currently underway in which bortezomib is being tested in combination with a pure anti-estrogen specifically in ERα-positive metastatic breast cancer (NCT01142401).